Mankind Pharma acquires Rivotril brand for India, reinforcing focus on chronic CNS therapies

Mankind Pharma Limited has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. The acquisition builds on Mankind Pharma’s growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas. Mankind Pharma will leverage its nationwide distribution network and large field force to support wider access to Rivotril across healthcare institutions and prescribers in India.